Century Therapeutics, Inc. Income Statement
IPSC|4 years of annual SEC 10-K data (FY2022-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$7M
FY2025
Gross Profit
N/A
FY2025
Operating Income
-$138M
FY2025
Net Income
-$127M
FY2025
Century Therapeutics, Inc. reported $7M in revenue and $127M in net loss for FY2025. Revenue has grown at a 8.2% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $6.6M | $2.2M | $5.2M | $5.2M |
| SG&A Expense | $33.2M | $34.7M | $31.9M | $19.2M |
| R&D Expense | $107.2M | $92.7M | $97.2M | $75.6M |
| Operating Income | -$138.1M | -$146.5M | -$133.8M | -$94.9M |
| Interest Expense | - | $540.0K | $1.0M | $1.3M |
| Income Tax | $1.8M | $1.9M | $91.0K | $43.0K |
| Net Income | -$126.6M | -$136.7M | -$130.9M | -$95.8M |
| EPS (Basic) | -$1.61 | -$2.30 | -$2.27 | -$2.96 |
| EPS (Diluted) | -$1.61 | -$2.30 | -$2.96 | -$2.96 |
| Shares Outstanding | 85.8M | 60.3M | 55.0M | 58.5M |
| Operating Margin | -2096.5% | -6556.9% | -2574.2% | -1825.0% |
| Profit Margin | -1920.9% | -6115.1% | -2518.4% | -1843.1% |